Gilead's Harvoni Wins Broader HCV Use
This article was originally published in Scrip
Executive Summary
Gilead Sciences Inc. won the FDA's blessing to market Harvoni (ledipasvir/sofosbuvir) for broader use in chronic hepatitis C virus (HCV) – granting the OK for the drug to be used in patients who have undergone liver transplant or who have decompensated cirrhosis.